Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression

Published:2020-12 Issue:2 Volume:1874 Page:188416
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Jena Bikash Chandra,Das Chandan Kanta,Bharadwaj Deblina,Mandal Mahitosh

Funder

CSIR, India

SERB, India

ICMR, India

DST-INSPIRE

MHRD Govt. of India

Indian Institute of Technology Kharagpur, India

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference176 articles.

1. Breast tumor stroma: A driving force in the development of resistance to therapies;Majidinia;Chem. Biol. Drug Des.,2017

2. Circulating and disseminated tumor cells: harbingers or initiators of metastasis?;Dasgupta;Mol. Oncol.,2017

3. Heritability of mammographic density, a risk factor for breast cancer;Boyd;N. Engl. J. Med.,2002

4. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going;Liang;Exp. Mol. Med.,2017

5. Coping with chemoresistance in prostate cancer—co-targeting of adipose stromal cells?;Bhagirath;Transl. Androl. Urol.,2019

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPIC-labeled CAFs: Key players in neoadjuvant chemotherapy resistance for gastric cancer;Translational Oncology;2024-10

2. Epigenetic modulation of long noncoding RNA H19 in oral squamous cell carcinoma-A narrative review;Non-coding RNA Research;2024-06

3. Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma;Cancers;2024-05-31

4. The combination ofSPP1knockdown and gemcitabine treatment enhances apoptosis and reduces invasiveness of pancreatic cancer cells;2024-05-06

5. Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT;Chem;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3